Should statins be paused or discontinued after thrombolysis or acute intracerebral hemorrhage? No!

Stroke

Volumn 44, Issue 5, 2013, Pages 1472-1476

  Scheitz, Jan F ^a   Nolte, Christian H ^a   Endres, Matthias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

discontinuation; intracerebral hemorrhage; statins; thrombolysis; withdrawal

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ATORVASTATIN; BISOPROLOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

AGED; APHASIA; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HEMIPARESIS; HUMAN; MALE; NOTE; PRIORITY JOURNAL;

BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84876865880     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000001     Document Type: Note

References (50)

1. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovas-cular disease or other high-risk conditions. Lancet. 2004;363:757-767.
2. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
3. Meier N, Nedeltchev K, Brekenfeld C, Galimanis A, Fischer U, Findling O, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arte-rial thrombolysis for acute ischemic stroke. Stroke. 2009;40:1729-1737.
4. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43:2904-2909.
5. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904-910.
6. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al.; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-123.
7. Laufs U, Endres M, Custodis F, Gertz K, Nickenig G, Liao JK, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation. 2000;102:3104-3110.
8. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43:147-154.
9. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, et al. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology. 2012;78:1678-1683.
10. Dowlatshahi D, Demchuk AM, Fang J, Kapral MK, Sharma M, Smith EE; Registry of the Canadian Stroke Network. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke. 2012;43:1518-1523.
11. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:556-562.
12. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol. 2005;25:287-294.
13. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, et al. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007;68:737-742.
14. Engelter ST, Soinne L, Ringleb P, Sarikaya H, Bordet R, Berrouschot J, et al. IV thrombolysis and statins. Neurology. 2011;77:888-895.
15. Rocco A, Sykora M, Ringleb P, Diedler J. Impact of statin use and lipid profile on symptomatic intracerebral haemorrhage, outcome and mortality after intravenous thrombolysis in acute stroke. Cerebrovasc Dis. 2012;33:362-368.
16. Nardi K, Engelter S, Strbian D, Sarikaya H, Arnold M, Casoni F, et al.; Lipid Profile in Thrombolysis Study Group. Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia. Neurology. 2012;79:1101-1108.
17. Alvarez-Sabín J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribó M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke. 2007;38:1076-1078.
18. Montaner J. Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation. Stroke. 2008;39:e6.
19. Cappellari M, Deluca C, Tinazzi M, Tomelleri G, Carletti M, Fiaschi A, et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study. J Neurol Sci. 2011;308:128-134.
20. Makihara N, Okada Y, Koga M, Shiokawa Y, Nakagawara J, Furui E, et al. Effect of serum lipid levels on stroke outcome after rt-PA therapy: SAMURAI rt-PA registry. Cerebrovasc Dis. 2012;33:240-247.
21. Martinez-Ramirez S, Delgado-Mederos R, Marín R, Suárez-Calvet M, Sáinz M P, Alejaldre A, et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis. J Neurol. 2012;259:111-118.
22. Miedema I, Uyttenboogaart M, Koopman K, De Keyser J, Luijckx GJ. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke. Cerebrovasc Dis. 2010;29:263-267.
23. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, Luijckx GJ, De Keyser J. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J Neurol. 2008;255:875-880.
24. Scheitz JF, Endres M, Heuschmann PU, Audebert HJ, Nolte CH. Reduced risk of poststroke pneumonia in thrombolyzed stroke patients with continued statin treatment. [published online ahead of print September 13, 2012] Int J Stroke. 2012.
25. Restrepo L, Bang OY, Ovbiagele B, Ali L, Kim D, Liebeskind DS, et al. Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fbrinolysis and percutaneous mechanical embolectomy. Cerebrovasc Dis. 2009;28:384-390.
26. Thomalla G, Sobesky J, Köhrmann M, Fiebach JB, Fiehler J, Zaro Weber O, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007;38:313-318.
27. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and infuence on clinical outcome: results of a prospective multi-center study. Stroke. 2008;39:2249-2256.
28. Molina CA, Alvarez-Sabín J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, et al. Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke. 2002;33:1551-1556.
29. Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Panda S, et al. MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin. J Neurol Sci. 2006;246:139-147.
30. Georgiadis AL, Hussein HM, Vazquez G, Shah Q, Suri MF, Ezzeddine MA, et al. Premorbid use of statins is associated with higher recanaliza-tion rates in patients with acute ischemic stroke undergoing endovascular treatment. J Neuroimaging. 2009;19:19-22.
31. Ford AL, An H, D'Angelo G, Ponisio R, Bushard P, Vo KD, et al. Preexisting statin use is associated with greater reperfusion in hyperacute ischemic stroke. Stroke. 2011;42:1307-1313.
32. Zhang L, Zhang ZG, Ding GL, Jiang Q, Liu X, Meng H, et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation. 2005;112:3486-3494.
33. Zhang L, Chopp M, Jia L, Cui Y, Lu M, Zhang ZG. Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab. 2009;29:1816-1824.
34. Endres M. Statins and stroke. J Cereb Blood Flow Metab. 2005;25:1093-1110.
35. Fisher M, Moonis M. Neuroprotective effects of statins: evidence from preclinical and clinical studies. Curr Treat Options Cardiovasc Med. 2012;14:252-259.
36. Biff A, Devan WJ, Anderson CD, Cortellini L, Furie KL, Rosand J, et al. Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. Stroke. 2011;42:1314-1319.
37. Stroke Treatment With Acute Reperfusion and Simvastatin. ClinicalTrials. gov. http://www.clinicaltrials.gov/ct2/show/NCT01073007. Accessed December 14, 2012.
38. Goldstein LB, Amarenco P, Szarek M, Callahan A III, Hennerici M, Sillesen H, et al.; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24 Pt 2):2364-2370.
39. Morgenstern LB, Hemphill JC III, Anderson C, Becker K, Broderick JP, Connolly ES Jr, et al.; American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108-2129.
40. Hackam DG, Austin PC, Huang A, Juurlink DN, Mamdani MM, Paterson JM, et al. Statins and intracerebral hemorrhage: a retrospective cohort study. Arch Neurol. 2012;69:39-45.
41. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124:2233-2242.
42. Karki K, Knight RA, Han Y, Yang D, Zhang J, Ledbetter KA, et al. Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage. Stroke. 2009;40:3384-3389.
43. Biff A, Devan WJ, Anderson CD, Ayres AM, Schwab K, Cortellini L, et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology. 2011;76:1581-1588.
44. Westover MB, Bianchi MT, Eckman MH, Greenberg SM. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol. 2011;68:573-579.
45. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. Stroke. 2006;37:2640-2643.
46. Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and molecular mechanisms. Pharmacotherapy. 2006;26:1288-1296.
47. Gertz K, Laufs U, Lindauer U, Nickenig G, Böhm M, Dirnagl U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke. 2003;34:551-557.
48. Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, et al.; GRACE Investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004;140:857-866.
49. Blanco M, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69:904-910.
50. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507.